Wanbury Ltd, one of the fastest growing pharma companies in the domestic market, has entered into the osteoporosis & gynaecology related calcium deficiency market with the launch of Cdense - calcium orotate, a mineral transporter. Cdense will be available in tablet form of 740 mg dosage.

Wanbury claims to be the only company in the country to use calcium orotate as a base to make the calcium supplement. The available calcium brands mainly use calcium carbonate as base. Global studies have shown that calcium orotate (Cdense) is the only calcium that directly deposits in the bone and ensures optimum bone mineralisation.  Cdense, which will be a 100 per cent prescription-based product, will be predominantly targeted at patients with osteoporosis, low back pain, postmenopausal women, and for calcium deficiency related to pregnancy, lactation and postpartum care.

"Wanbury's Cdense is the only once-a-day dosage product, which ensures 95 per cent absorption, powerful recalcification of the bone, reverses bone loss, relieves pain and has excellent gastro-intestinal (GI) tolerance leading to maximum patient compliance. The calcium brands that are currently available in the market have to be taken twice or thrice a day, leading to GI irritation," said Dr Rajaram Samant, director-Marketing & Sales, Wanbury.